GSK’s cancer drug Jemperli has met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after treatment for a specific type of locally advanced rectal cancer.
Trial Details
The trial, known as AZUR-1, tested Jemperli in rectal cancer tumors that cannot properly repair DNA damage, a subtype affecting 5%-10% of 730,000 annual global cases. Current standard of care typically includes chemotherapy, radiation, and surgery, and can lead to lifelong colostomy bag use and infertility.
The interim data from the trial also showed Jemperli’s safety and tolerability profile was consistent with previous studies in solid tumors. Jemperli, already approved in the U.S. and UK for specific endometrial cancer subtypes, generated sales of $1.1 billion in 2025.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
